3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Multiple Myeloma
2
Lymphoma
2
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
fludarabine phosphate
55
Cyclophosphamide
49
Peripheral Blood Stem Cell Transplantation
47
Mycophenolic Acid
40
Tacrolimus
38
Whole-Body Irradiation
32
Busulfan
27
Cyclosporine
25
Antilymphocyte Serum
25
Methotrexate
21
Filgrastim
21
fludarabine
19
Melphalan
19
Radiotherapy
14
Methylprednisolone
13
Sirolimus
11
Flow Cytometry
10
Etoposide
10
Alemtuzumab
10
Cord Blood Stem Cell Transplantation
9
Rituximab
8
Psychiatric Rehabilitation
8
Granulocyte Colony-Stimulating Factor
8
Therapeutics
7
Polymerase Chain Reaction
7
thymoglobulin
6
sargramostim
5
Prednisone
5
Ondansetron
4
Immunologic Techniques
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Tinzaparin
×
Plasma cell
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled